Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Surgical & Medical Instruments & Apparatus

electroCore, Inc. to acquire NeuroMetrix, Inc.

Announced Dec 17, 2024 · Closed May 1, 2025

Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash

Transaction

Acquirer
electroCore, Inc. (ECOR)
Target
NeuroMetrix, Inc. (NURO)
Buyer type
Strategic
Offer price per share
—
Enterprise value
—
Status
Closed May 1, 2025

Deal protections

Break fee (target pays)
$0.5M
Reverse fee (buyer pays)
—
Go-shop
—
Financing
—

Advisors

To the acquirer
Not disclosed
To the target
Not disclosed

Sector context · Healthcare

Comparable deals
92 in the prior 24 months
Premium
Sector median 67.0%
EV / Adj. EBITDA
Sector median 14.5x
Break fee
Sector median 3.5%

Timeline

  1. AnnouncedDec 17, 2024
  2. Proxy filedJan 30, 2025
  3. Definitive proxyFeb 14, 2025
  4. Shareholder voteMar 21, 2025
  5. ClosedMay 1, 2025
Sources
  • 8-K · Dec 17, 2024

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.